You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 4
  • 386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab

Article metrics

Article menu

Download PDFPDF

Endometrial cancer
386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
Free

 

Online download statistics by month:

Online download statistics by month: December 2020 to October 2024

AbstractFullPdf
Dec 202058010
Jan 20213709
Feb 20212107
Mar 20213005
Apr 20213605
May 202111010
Jun 2021404
Jul 2021009
Aug 2021306
Sep 20214012
Oct 202126020
Nov 202128019
Dec 20212807
Jan 20221804
Feb 20221606
Mar 2022702
Apr 202218011
May 20221408
Jun 202225010
Jul 202247011
Aug 20222209
Sep 20221005
Oct 20222204
Nov 20221306
Dec 20222705
Jan 20232103
Feb 20231803
Mar 20232104
Apr 2023403
May 2023901
Jun 2023600
Jul 2023405
Aug 20232005
Sep 2023802
Oct 2023901
Nov 20231003
Dec 20232600
Jan 2024600
Feb 20241604
Mar 20241306
Apr 20241802
May 20241401
Jun 20242605
Jul 20241202
Aug 20242105
Sep 20241901
Oct 2024600
Total8320260